Don’t Count Those Pennies Just Yet: Watson Cited For Claiming Cost Savings From Sodium Ferric Gluconate
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Office of Prescription Drug Promotion objected to economic claims that the product could reduce ESA use in part because they were based on a subset of the approved population.
You may also be interested in...
Rapaflo Symptom Relief ≠ Clinical Evidence, FDA Says
FDA objects to image and headline on Actavis webpage suggesting benign prostatic hyperplasia treatment improves sleep quality and work productivity; company has revised the site.
Present Serious, Not Common, Risks First, FDA Tells Watson In Letter On Gelnique
"Restroom stall cling" for the urinary incontinence drug used at medical meeting gets notice of violation letter from DDMAC.
AstraZeneca Diprivan Anti-Generic Promos Require Corrective Letter - FDA
AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.